Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01338818 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 299
- Enrollment target
NCT01338818 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 299 participants.
The verdict
NCT01338818, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 299 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
Interventions
- DRUG Ritalin LA (methylphenidate hydrochloride extended release)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01338818
The ClinicalTrials.gov registry entry for NCT01338818 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ritalin LA (methylphenidate hydrochloride extended release) is the first listed.
NCT01338818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01338818 about?
NCT01338818 is a clinical study titled "Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder". This study will evaluate the long-term safety of methylphenidate hydrochloride extended release in adults with attention deficit/hyperactivity disorder
What is the current status of trial NCT01338818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 2011-04. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01338818?
The interventions under investigation include: Ritalin LA (methylphenidate hydrochloride extended release) (DRUG).
Who is sponsoring clinical trial NCT01338818?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.